论文部分内容阅读
原癌基因人类表皮生长因子受体2(HER-2)阳性炎性乳腺癌是指HER-2过表达或扩增的炎性乳腺癌。临床上以乳房表面皮肤呈炎性改变而没有溃疡形成、局部及全身快速进展为特点,表现出更高的侵袭性。尽管炎性乳腺癌预后差,但新辅助化疗、手术及放疗等多学科综合治疗,尤其是分子靶向治疗显著改变了本病的自然进程。本文就近年来HER-2阳性炎性乳腺癌的分子靶向治疗进展作一综述。
Proto-Oncogene Human Epidermal Growth Factor Receptor 2 (HER-2) -positive Inflammatory breast cancer refers to inflammatory breast cancer over-expressing or expanding HER-2. Clinically, the breast surface of the skin was an inflammatory change without the formation of ulcers, local and systemic rapid progress is characterized by showing higher invasiveness. Despite the poor prognosis of inflammatory breast cancer, multidisciplinary treatments such as neoadjuvant chemotherapy, surgery and radiotherapy, and molecular targeted therapy in particular, have dramatically altered the natural course of the disease. This article reviews the progress of molecular targeted therapy of HER-2-positive inflammatory breast cancer in recent years.